Could an ancient remedy cut early deaths in leukemia?
NCT ID NCT07503730
First seen Apr 01, 2026 · Last updated Jun 13, 2026 · Updated 14 times
Summary
This study tests whether giving a Chinese herbal medicine called Realgar-Indigo naturalis formula (RIF) together with standard vitamin A therapy right away can lower the risk of early death in people with a fast-growing blood cancer called acute promyelocytic leukemia (APL). About 224 adults with suspected APL will be randomly assigned to get either RIF plus standard care or standard care alone before their diagnosis is confirmed. The goal is to see if early RIF reduces deaths within the first 30 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi'an, Shaanxi, 710061, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.